Navigation Links
Watson Launches Generic AMRIX®
Date:5/16/2011

PARSIPPANY, N.J., May 16, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc.  AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal conditions.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

Under the terms of the non-exclusive sales agent agreement, Anesta manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States on behalf of Anesta and will receive payments based on sales of the product. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending March 31, 2011, AMRIX had sales of approximately $125 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.  

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

AMRIX® is a registered trademark of Cephalon, Inc.  CONTACTS: Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Concerta®
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
3. Watson First Quarter 2011 Net Revenue Increases to $877 Million
4. New Life Agency Adds Watson to Join Walgreens on The Fertility Pharmacy Care Card for Fertility Medication
5. Watson Confirms Welchol® Patent Challenge
6. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
7. Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings
8. Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia
9. Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
10. Watson Confirms OxyContin® Patent Challenge
11. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... 2017 Michael Penna , President and ... opportunities for growth in his response to the July ... is seeking a buyer for eMDs. Penna,s company, Complete ... solutions Value Added Reseller and national leader in the ... "As the healthcare market continues to dictate consolidation, ...
(Date:8/29/2017)... ivWatch, LLC, the leading provider of continuous monitoring devices ... been awarded an Innovative Technology contract from Vizient, Inc., the largest ... ... the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch ...
(Date:8/25/2017)... Zed ( www.innovationzed.com ), an Irish medtech company, today announced that it ... and Bassetlaw, England . The collaboration ... part of a national NHS Test Bed programme exploring new models of ... Innovation Zed ... Connect, a snap-on accessory for disposable insulin pen users, automatically collects and ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: ... even the lost, have value to God. “Letters From Home” is the creation of ... member of the President’s Cabinet of Jerry Savelle Ministries International, who has traveled and ...
(Date:9/21/2017)... ... , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as ... that Plastic Surgeon Kiranjeet Gill has been awarded as one of the 15th annual ... that was started in 2003 to salute young achievers in Southwest Florida who have ...
(Date:9/21/2017)... ... September 21, 2017 , ... Hair ... new member survey conducted by the International Society of Hair Restoration Surgery ... to 2016 rose 60 percent, with 635,189 procedures performed in 2016. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center ... announced today the election of Yie-Hsin Hung to the Board of Directors. , ... Board of Directors. Ms. Hung is an invaluable addition to our team,” said Vincent ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... operators, announces the acquisition of Isle at Kingwood Assisted Living and Memory Care ... an established retirement community with 55 assisted living apartments, 43 memory care apartments ...
Breaking Medicine News(10 mins):